drugset / Trial / NCT00125372
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Completed
12 enrolled
Dartmouth-Hitchcock Medical Center
Genentech, Inc. · collabLigand Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
Timeline
- Start
- 2005-12
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexarotene | Small molecule | 400 mg/m2 | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |